MA
FLNA

Montag & Associates’s Filana Therapeutics FLNA Stock Holding History

Montag & Associates’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,000
Closed -$58.9K – 1031
2024
Q3 		$58.9K Buy
2,000
+500
+33% +$11.5K ﹤0.01% 581
2024
Q2 		$18.5K Hold
1,500
– – ﹤0.01% 711
2024
Q1 		$30.4K Hold
1,500
– – ﹤0.01% 657
2023
Q4 		$33.8K Hold
1,500
– – ﹤0.01% 629
2023
Q3 		$25K Buy
1,500
+500
+50% +$9.91K ﹤0.01% 645
2023
Q2 		$24.5K Hold
1,000
– – ﹤0.01% 657
2023
Q1 		$24.1K Hold
1,000
– – ﹤0.01% 650
2022
Q4 		$29.5K Hold
1,000
– – ﹤0.01% 618
2022
Q3 		$42K Hold
1,000
– – ﹤0.01% 571
2022
Q2 		$28K Buy
1,000
+500
+100% +$12.6K ﹤0.01% 612
2022
Q1 		$19K Hold
500
– – ﹤0.01% 671
2021
Q4 		$22K Sell
500
-95
-16% -$4.98K ﹤0.01% 663
2021
Q3 		$37K Hold
595
– – ﹤0.01% 598
2021
Q2 		$51K Buy
+595
New +$31.9K ﹤0.01% 551

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Montag & Associates's FLNA Position: Q4 2024 in Review

Montag & Associates sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 2,000 shares — an estimated $58.9K sold.

Montag & Associates first reported a position in FLNA in Q2 2021 and held it in 14 quarters. The position peaked at $58.9K in Q3 2024. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

  • Montag & Associates reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Montag & Associates sold 2,000 Filana Therapeutics shares in Q4 2024, an estimated $58.9K.
  • Montag & Associates first reported a position in Filana Therapeutics in Q2 2021 and held it in 14 quarters.
  • Montag & Associates's Filana Therapeutics position peaked at $58.9K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on Montag & Associates's 13F filing for Q4 2024, filed 30 Jan 2025.